Galderma Group N

Active

GALD.SW

Company Overview

Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in …

Market Cap
41.04B CHF
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
Switzerland
Currency
CHF
Asset Type
Common Stock
Price Analysis
Key Metrics

Wall Street Target

$194.37

PE Ratio (TTM)

59.46

Forward PE

45.66

Earnings per Share

$2.96

Dividend per Share

$0.44

Valuation

Market Cap

41.04B

EBITDA

1.39B

Profit Margin

0.1457%

Dividend Yield

0.00%

Price / Sales (TTM)

6.930x

EPS Estimate (Current)

3.729

EPS Estimate (Next Year)

6.690

EV / Revenue

8.870x

EV / EBITDA

36.830x

Revenue Growth (YoY)

0.277%

Earnings Growth (YoY)

1.307%

Share Statistics

Shares Outstanding

233.19M

Shares Float

130.09M

% Insiders

21.02%

% Institutions

47.95%

Float Ratio

55.79%

Normal (Float ≤ Outstanding)

Company Information

Address

Zählerweg 10
Zug 6300
Switzerland

Employees

7676

Officers

Dr. Flemming Ornskov M.B.A., M.D., M.P.H.

CEO & Director

Born 1958

Mr. Adrian Murphy

Head of Global Operations

Born 1970

Mr. Christian Marcoux

Chief Communications Officer

Mr. Emil Ivanov

Head of Strategy, Investor Relations & ESG

Mr. Luigi Felice La Corte

Chief Financial Officer

Born 1969

Ms. Desislava Lazarova M.D.

Global Head of Customer Education & Training

Ms. Nakisa Serry J.D., MBA

General Counsel, Chief Compliance Officer & Interim CHRO

Calendar
Last Earnings

2026-07-23

AMC Period 2026-06-30
Act
Est 1.27
Surp
Earnings

Recent quarters & estimate trends

View full earnings (7)
Period EPS Act. EPS Est. Surprise
Dec 2026
Jun 2026 1.27
Mar 2026 1.14
Dec 2025 1.41
Jun 2025 0.82 0.00
Dec 2024 0.77 0.84 -8.33%
Jun 2024 0.55 1.12 -50.89%

Estimate trends

Dec 2027

6.69 EPS est.

40.0% growth

Dec 2026

3.73 EPS est.

44.0% growth

Sep 2026

1.03 EPS est.

Jun 2026

1.27 EPS est.